ARTICLE | Clinical News

Kura reports Phase II data for tipifarnib in CMML

January 5, 2018 10:26 PM UTC

Kura Oncology Inc. (NASDAQ:KURA) reported preliminary data from nine evaluable patients with wild-type RAS chronic myelomonocytic leukemia (CMML) in a Phase II trial showing that tipifarnib led to an overall response rate (ORR) of 33%, plus 6 cases of stable disease. In seven evaluable patients with mutant RAS CMML, tipifarnib led to 6 cases of stable disease. Tipifarnib was generally well tolerated. Data were presented at the American Society of Hematology meeting in Atlanta.

Patients received twice-daily oral tipifarnib at a starting dose of 900 mg on days 1-7 and 15-21 of each 28-day cycle. Secondary endpoints in the open-label, U.S. trial include progression-free survival (PFS), duration of response and safety. Additional data from the trial are expected this year...